Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PZ HTL SA

Underlying Mechanism Identified for Prostate Cancer Caused by Cadmium

By BiotechDaily International staff writers
Posted on 18 Apr 2012
The widespread, extremely toxic heavy metal cadmium, classified as a Group 1 human carcinogen by the International Agency for Research on Cancer and the US National Toxicology Program, has now been shown to induce apoptosis resistance related to carcinogenesis in human prostrate cells.

An established lung carcinogen in humans, cadmium has also been suspected of playing a role in the induction and the development of prostate cancer, one of the most commonly diagnosed cancers in men. Though multiple molecular targets have been identified, which suggests that more than a single pathway may be involved, specific molecular events of the underlying mechanism(s) have remained elusive. It has been hypothesized that a key factor in cadmium-induced malignant transformation is acquisition of apoptotic resistance. In the present study, published online March 20, 2012, in the journal PLoS ONE, scientists investigated cultured cells derived from human prostate epithelium for effects of cadmium exposure on apoptosis and on the expression of some tumor suppressor proteins.

Initially, the normal RWPE-1 cell line was tested and compared with the response of its cadmium-transformed derivative CTPE. Subsequently, different prostate cancer cell lines were analyzed, including primary adenocarcinoma (22Rv1 and CWR-R1) and metastatic adenocarcinoma cells (LNCaP, PC-3, and DU145). Cells were treated for 24 hours with different concentrations of CdCl(2) , upon which apoptosis, cell cycle distribution, and expression of tumor suppressor proteins were analyzed. Concentrations relevant to human exposure were used: cadmium concentrations (10-30 µM) that are within the range that have been found in normal, hypertrophic, and malignant human prostate tissues and that, at the same time, are able to trigger apoptosis in cell culture systems.

Cellular response to cadmium was also evaluated after siRNA-mediated p53 silencing in wild type p53-expressing RWPE-1 and LNCaP cells, and after adenoviral p53 overexpression in p53-deficient DU145 and PC-3 cell lines. These and additional data showed that p53 silencing was able to suppress cadmium-induced apoptosis. The results demonstrated that cadmium can induce p53-dependent apoptosis in human prostate epithelial cells and suggest p53 mutation as a possible contributing factor for the acquisition of apoptotic resistance in cadmium prostatic carcinogenesis.

“In our study, we investigated the effects of cadmium exposure in normal and in tumor cells derived from human prostate tissue,” said Dr. Pier Paolo Claudio, lead scientist of the study and associate professor in the Biomedical Sciences Graduate Program and Department of Biochemistry and Microbiology in the Joan C. Edwards School of Medicine at Marshall University (Huntington, WV, USA). “The focus of work in our laboratory is to understand the molecular mechanisms governing malignant transformation in order to tailor novel therapeutic strategies. To effectively design novel biological drugs, a thorough understanding of the mechanism of cancer pathogenesis is required,” he added.

The authors, part of a collaborative effort between multiple institutions in Italy and the USA, noted that since the acquisition of apoptotic resistance appears to be crucial in cadmium-induced malignant transformation, further characterization of the pathways involved as well as a thorough comparative proteome analysis of the different prostate epithelial cells studied would significantly improve understanding of cadmium carcinogenesis in the prostate.

Related Links:

Marshall University




BIOSIGMA S.R.L.
SLAS - Society for Laboratory Automation and Screening
RANDOX LABORATORIES
comments powered by Disqus

Channels

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Lab Technologies

view channel
Image: On target: When researchers introduced nanobodies they made to cells engineered to express a tagged version of a protein in skeletal fibers known as tubulin (red), the nanobodies latched on. The cells above have recently divided (Photo courtesy of Rockefeller University).

Turning Antibodies into Precisely Tuned Nanobodies

New technology has the potential to create nanobodies making them much more accessible than antibodies for all sorts of research. Antibodies control the process of recognizing and zooming in on molecular... Read more

Business

view channel

Two Industry Partnerships Initiated to Fuel Neuroscience Research

Faster, more complex neural research is now attainable by combining technology from two research companies. Blackrock Microsystems, LLC (Salt Lake City, UT, USA), a developer of neuroscience research equipment, announced partnerships with two neuroscience research firms—PhenoSys, GmbH (Berlin, Germany) and NAN Instruments, Ltd.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.